PolyPid Yönetim

Yönetim kriter kontrolleri 4/4

PolyPid CEO'su Dikla Czaczkes Akselbrad, Jul2022 tarihinde atandı, in görev süresi 2.33 yıldır. in toplam yıllık tazminatı $ 557.44K olup, şirket hissesi ve opsiyonları dahil olmak üzere 62.4% maaş ve 37.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.007% ine doğrudan sahiptir ve bu hisseler $ 1.54K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 4.5 yıldır.

Anahtar bilgiler

Dikla Czaczkes Akselbrad

İcra Kurulu Başkanı

US$557.4k

Toplam tazminat

CEO maaş yüzdesi	62.4%
CEO görev süresi	2.3yrs
CEO sahipliği	0.007%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	4.5yrs

Son yönetim güncellemeleri

Recent updates

PolyPid set to cut 20% jobs

Oct 20

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

Sep 28

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

Sep 02

PolyPid GAAP EPS of -$1.23 misses by $0.60

Aug 10

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

Aug 03

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Mar 09

PolyPid's oncoplex cancer program shows encouraging action in animal study

Dec 22

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

Dec 16

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

Nov 24

CEO Tazminat Analizi

Dikla Czaczkes Akselbrad'un ücretlendirmesi PolyPid'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$24m
Dec 31 2023	US$557k	US$348k	-US$24m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$34m
Dec 31 2022	US$749k	US$356k	-US$40m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	US$848k	US$382k	-US$43m
Sep 30 2021	n/a	n/a	-US$41m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$46m
Dec 31 2020	US$1m	US$261k	-US$43m

Tazminat ve Piyasa: Dikla 'ın toplam tazminatı ($USD 557.44K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 653.78K ).

Tazminat ve Kazançlar: Dikla 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dikla Czaczkes Akselbrad (51 yo)

2.3yrs

Görev süresi

US$557,441

Tazminat

Ms. Dikla Czaczkes Akselbrad was an Executive Vice President and Chief Financial Officer of PolyPid Ltd. since December 2016 until July 1, 2022 and serves as its Chief Executive Officer since July 1, 2022...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dikla Czaczkes Akselbrad	CEO & Director	2.3yrs	US$557.44k	0.0069% $ 1.5k
Jonny Missulawin	Chief Financial Officer	2.3yrs	US$379.57k	Veri yok
Dalit Hazan	Deputy CEO and Executive VP of R&D	3.4yrs	US$598.18k	Veri yok
Ori Warshavsky	Chief Operating Officer - US	no data	US$512.92k	0.0039% $ 880.1
Maria Rubin	Vice President of Operations	1.5yrs	Veri yok	Veri yok
Tal Vilnai	General Counsel & Corporate Secretary	2.8yrs	Veri yok	Veri yok
Rivi Lev-ari	Vice President of Human Resource	no data	Veri yok	Veri yok
Jean-Marc Hagai	Chief Commercial Officer	2.8yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim: PYPD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dikla Czaczkes Akselbrad	CEO & Director	2.3yrs	US$557.44k	0.0069% $ 1.5k
Robert Stein	Independent Director	4.4yrs	Veri yok	Veri yok
Itzhak Krinsky	Independent Director	5.8yrs	Veri yok	0.012% $ 2.7k
Yafit Stark	Clinical Development Strategy Advisor	no data	Veri yok	Veri yok
Noam Emanuel	Member of Scientific Advisory Board of Drug Delivery	less than a year	US$471.47k	Veri yok
Yechezkel Barenholz	Independent Director	16.6yrs	Veri yok	0.041% $ 9.1k
Nir Dror	Independent Director	4.5yrs	Veri yok	Veri yok
Jacob Harel	Independent Chairman	7yrs	Veri yok	0.0069% $ 1.5k
Moshe Salai	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Erez Kachel	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Hartzell Schaff	Member of Scientific Advisory Board	7.8yrs	Veri yok	Veri yok
Frederick Lang	Member of Scientific Advisory Board	3yrs	Veri yok	Veri yok

4.5yrs

Ortalama Görev Süresi

69.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PYPD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).

PolyPid Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

PolyPid Ltd., Annual General Meeting, Jul 02, 2024

Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors

PolyPid Ltd. Announces Board Changes

PolyPid Ltd. Announces Executive Changes

PolyPid Ltd., Annual General Meeting, May 03, 2022

PolyPid Ltd. Announces CEO Changes

Recent updates

PolyPid Ltd. to Report Q3, 2024 Results on Nov 13, 2024

PolyPid Ltd. to Report Q2, 2024 Results on Aug 14, 2024

PolyPid Ltd. Hosts Kol Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on Its Ongoing Shield II Phase 3 Trial

PolyPid Ltd., Annual General Meeting, Jul 02, 2024

PolyPid Ltd. Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. to Report Q1, 2024 Results on May 08, 2024

PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial

PolyPid Ltd. to Report Q4, 2023 Results on Feb 14, 2024

PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.

PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors

Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors

PolyPid Ltd. to Report Q3, 2023 Results on Nov 08, 2023

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PolyPid Announces Reverse Share Split to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement

PolyPid Ltd. Announces Successful Completion of Manufacturing Process Validation for D-PLEX100

PolyPid Ltd. to Report Q2, 2023 Results on Aug 09, 2023

Polypid Ltd. Announces New Publication Highlighting Potent Antibacterial Activity of D-Plex Against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

PolyPid Ltd. Announces Recruitment of First Patient in Revised Shield Ii Phase 3 Trial Evaluating D-Plex100 for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

PolyPid Ltd Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. Announces Board Changes

PolyPid Ltd. to Report Q4, 2022 Results on Feb 08, 2023

PolyPid Provides Positive Regulatory Update for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Polypid Ltd. Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-Hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

Price target decreased to US$3.38

PolyPid Ltd. to Report Q3, 2022 Results on Nov 09, 2022

PolyPid set to cut 20% jobs

Polypid Ltd. Announces Eligibility for European Medicines Agency Centralized Procedure for D-Plex100 for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX100 in the Prevention of Surgical Site Infections in Abdominal Surgery

Price target increased to US$24.33

PolyPid Ltd. Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

PolyPid GAAP EPS of -$1.23 misses by $0.60

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

PolyPid Ltd. to Report Q2, 2022 Results on Aug 10, 2022

Polypid Ltd Announces Completion of Enrollment in Phase 3 Shield I Trial of D-Plex for Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

PolyPid Ltd. Announces Executive Changes

PolyPid: Strong Pipeline, Close Catalysts

PolyPid Ltd. announced that it expects to receive $15 million in funding from Kreos Capital Management (UK) Limited

PolyPid Ltd., Annual General Meeting, May 03, 2022

Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

PolyPid Ltd. Announces 750Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 in Abdominal Surgery

PolyPid Ltd. Announces 750Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 in Abdominal Surgery

PolyPid Ltd. Announces CEO Changes

Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

PolyPid Ltd. Announces Positive FDA Type B Meeting Feedback for D-Plex Development Program

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid Ltd., Annual General Meeting, Apr 13, 2021

Polypid Ltd. Announces 100Th Patient Enrolled in Shield I Phase 3 Clinical Trial of D-Plex100 for the Prevention of Post-Abdominal Surgery Incisional Infections

New 90-day high: US$12.75

PolyPid Ltd. to Report Q4, 2020 Results on Feb 10, 2021

PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program

PolyPid's oncoplex cancer program shows encouraging action in animal study

PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

New 90-day low: US$9.98

PolyPid Ltd. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: US$11.00

PolyPid Ltd. to Report Q2, 2020 Results on Aug 19, 2020

CEO Tazminat Analizi

CEO